Unigestion Holding SA Has $19.23 Million Position in Johnson & Johnson (NYSE:JNJ)

Unigestion Holding SA lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 57.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 115,969 shares of the company's stock after selling 153,455 shares during the quarter. Johnson & Johnson comprises approximately 1.1% of Unigestion Holding SA's holdings, making the stock its 26th largest holding. Unigestion Holding SA's holdings in Johnson & Johnson were worth $19,232,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. WealthTrak Capital Management LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. bought a new position in Johnson & Johnson in the fourth quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $32,000. Conquis Financial LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $33,000. Finally, Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson in the 4th quarter valued at $36,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Johnson & Johnson stock traded up $0.28 during mid-day trading on Thursday, hitting $153.50. 5,277,704 shares of the company's stock traded hands, compared to its average volume of 7,929,000. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a 50 day simple moving average of $153.81 and a two-hundred day simple moving average of $153.67. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The stock has a market cap of $369.32 billion, a price-to-earnings ratio of 23.08, a P/E/G ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.39%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on JNJ. Barclays dropped their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Royal Bank of Canada reiterated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday. Finally, Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.